|
Noha Abdeljawad ☆ Cairo, Egypt, 2013-02-26 10:08 (4868 d 03:17 ago) Posting: # 10119 Views: 4,908 |
|
|
Hello Everyone, Sulindac sulfoxide is a prodrug with no pharmacological activity. It is water-soluble and readily absorbed from the intestine then undergoes two major biotransformation reactions: a reversible reduction into a Sulfide which is pharmacologically active and an irreversible oxidation into a Sulfone. My question is, in a bioequivalence study comparing sulindac tablet formulations, which analytes will the 90% CI be based on; the parent compound and the sulfide (active metabolite) or the sulfide only or the parent compound only? I couldn’t find an FDA guidance paper for sulindac. — Best Regards Noha Abdeljawad |
|
Helmut ★★★ ![]() Vienna, Austria, 2013-02-26 16:33 (4867 d 20:51 ago) @ Noha Abdeljawad Posting: # 10124 Views: 4,054 |
|
|
Dear Noha, which regulatory agency is your “target”? Examples:
— Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
|
Noha Abdeljawad ☆ Cairo, Egypt, 2013-03-05 12:11 (4861 d 01:13 ago) @ Helmut Posting: # 10152 Views: 3,834 |
|
|
According to the EDA Thanks, Helmut — Best Regards Noha Abdeljawad |

FDA![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
![[image]](https://static.bebac.at/img/CC by.png)
